Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2010
11/18/2010WO2010130643A1 Lactoferrin and brain health and development in infants
11/18/2010WO2010130424A1 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
11/18/2010WO2010130423A1 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
11/18/2010WO2010130422A1 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
11/18/2010WO2010130063A1 The little molecule compound which used for promoting the stem cells hyperplasia and the use thereof
11/18/2010WO2010111626A3 Poly (adp-ribose) polymerase (parp) inhibitors
11/18/2010WO2010102171A3 Secreted ap2 and methods of inhibiting same
11/18/2010WO2010100133A3 Indole derivatives for treating neurodegenerative diseases
11/18/2010WO2010085799A9 Compositions and method for the treatment of parkinson's disease
11/18/2010WO2010080603A9 Method of treatment of aggression
11/18/2010WO2010076564A3 Isochromenones useful in the treatment of inflammation
11/18/2010WO2010071846A3 Compounds for treating neuropsychiatric conditions
11/18/2010WO2010069605A3 Oxidized cardiolipin as a novel pro-inflammatory factor
11/18/2010WO2010067078A3 3,6-disubstituted xanthylium salts as medicaments
11/18/2010WO2010056644A8 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
11/18/2010WO2010049952A3 A novel process for the preparation of eletriptan
11/18/2010WO2010045251A3 Spiro-oxindole compounds and their use as therapeutic agents
11/18/2010WO2010039186A3 Benzoxazoles useful as faah modulators and uses thereof
11/18/2010WO2010033168A3 Modulators of p2x3 receptor activity
11/18/2010WO2010017466A3 Phenobarbital salts; methods of making; and methods of use thereof
11/18/2010WO2009108390A3 Method for achieving desired glial growth factor 2 plasma levels
11/18/2010WO2007133816A3 Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
11/18/2010US20100292734 Multi-layer osteoinductive, osteogenic, and osteoconductive carrier
11/18/2010US20100292346 Stereoisomers Propofol Therapeutic Compounds
11/18/2010US20100292345 Therapeutic uses of cannabigerol
11/18/2010US20100292344 Methods and Compositions for Treating Thalamocortical Dysrhythmia
11/18/2010US20100292341 Quick dissolve compositions of memantine hydrochloride
11/18/2010US20100292340 Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine
11/18/2010US20100292337 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same
11/18/2010US20100292336 Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same
11/18/2010US20100292334 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors
11/18/2010US20100292330 Compositions and methods for enhancing cognitive function
11/18/2010US20100292320 Benzofuran anilide histone deacetylase inhibitors
11/18/2010US20100292295 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
11/18/2010US20100292292 Treatment of Neurodegenerative Diseases Using Indatraline Analogs
11/18/2010US20100292290 Novel process to prepare almotriptan
11/18/2010US20100292289 Treatment of metabolic syndrome with novel amides
11/18/2010US20100292288 Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
11/18/2010US20100292283 Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators
11/18/2010US20100292282 Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
11/18/2010US20100292281 Treatment of mci and alzheimer's disease
11/18/2010US20100292279 Bis-(Sulfonylamino) Derivatives in Therapy
11/18/2010US20100292276 Benzimidazole derivatives useful as trp m8 receptor modulators
11/18/2010US20100292273 Cannabinoid Receptor Modulators
11/18/2010US20100292271 Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor
11/18/2010US20100292266 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase
11/18/2010US20100292256 (EN) 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO [1,5-A]PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF
11/18/2010US20100292254 Fused Pyrimidine Derivatives as Trpv3 Modulators
11/18/2010US20100292252 Vinyl-aryl derivatives for inflammation and immune-related uses
11/18/2010US20100292250 CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF
11/18/2010US20100292248 Combination preparations comprising slv308 and a dopamine agonist
11/18/2010US20100292245 (en) substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
11/18/2010US20100292244 Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
11/18/2010US20100292243 7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
11/18/2010US20100292242 Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
11/18/2010US20100292241 3,5-substituted-1,3-oxazolidin-2-one derivatives
11/18/2010US20100292240 Sulfonamide compounds
11/18/2010US20100292238 Phenoxymethyl Heterocyclic Compounds
11/18/2010US20100292235 Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
11/18/2010US20100292234 Triazole fused heteroaryl compounds and methods of use thereof
11/18/2010US20100292228 Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
11/18/2010US20100292224 Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
11/18/2010US20100292221 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/18/2010US20100292220 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/18/2010US20100292217 Ranolazine for the treatment of cns disorders
11/18/2010US20100292216 Methods and Compositions for the Treatment of Psychiatric Conditions
11/18/2010US20100292211 Antipsychotic treatment based on snp genotype
11/18/2010US20100292210 Novel Compounds for A-Beta-Related Pathologies
11/18/2010US20100292209 Methods for identifying compounds that modulate neurotrophic factor signaling
11/18/2010US20100292205 Pyrimidone Compounds As GSK-3 Inhibitors
11/18/2010US20100292204 Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
11/18/2010US20100292197 Compositions and Methods for Increasing Telomerase Activity
11/18/2010US20100292195 Low burst polymers and methods to produce polymer
11/18/2010US20100292188 Compounds Comprising A Cyclobutoxy Group
11/18/2010US20100292157 Combination Treatments for Alzheimer's Disease and Similar Diseases
11/18/2010US20100292149 Modulation of the Neuroendocrine System as a Therapy for Motor Neuron Disease
11/18/2010US20100292148 Targeted polylysine dendrimer therapeutic agent
11/18/2010US20100292142 Novel neurotrophic factors
11/18/2010US20100292132 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
11/18/2010US20100292129 Methods and Compositions for Enhancing Proteasome Activity
11/18/2010US20100291233 Treatment of neurological disorders
11/18/2010US20100291228 Scavenger of in vivo harmful reactive oxygen species and/or free radicals
11/18/2010US20100291225 Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
11/18/2010US20100291208 Controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof
11/18/2010US20100291205 Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
11/18/2010US20100291204 Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use thereof
11/18/2010US20100291203 Opioid Agonist/Antagonist Combinations
11/18/2010US20100291196 Method of treatment of autism spectrum disorder with liposomal reduced glutathione
11/18/2010US20100291191 Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
11/18/2010US20100291182 Drug-Loaded Fibers
11/18/2010US20100291180 Nerve guidance tubes
11/18/2010US20100291160 Pharmaceutical system for trans-membrane delivery
11/18/2010US20100291158 Sustained release oral composition of an antipsychotic agent
11/18/2010US20100291151 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
11/18/2010US20100291149 Attenuated listeria spp. and methods for using the same
11/18/2010US20100291136 Pharmaceutical Liquid Composition of Botulinum Toxin With Improved Stability
11/18/2010US20100291122 Method for enhancing immune response with peptide
11/18/2010US20100291119 Alpha B crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
11/18/2010US20100291102 Therapeutic Agent
11/18/2010US20100291099 Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
1 ... 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 ... 1833